Iwa mimọ giga 540737-29-9 Tofacitinib citrate fun JAK Pathway Inhibitor
| Ọjaoruko | Tofacitinib Citrate |
| Awọn itumọ ọrọ sisọ | (3R,4R) -1- (Cyanoacetyl) -4-methyl-N-methyl-N-1H-pyrrolo [2,3-d] pyrimidin-4-yl-3-piperidinamine 2-hydroxy-1,2,3 - propanetricarboxylate;CP 690500-10;CP 690550-10;(3R,4R) -4-Methyl-3- (methyl-7H-pyrrolo [2,3-d] pyrimidin-4-ylamino) -beta-oxo-1-piperidinepropanenitrile 2-Hydroxy-1,2,3-propanetricarboxylate |
| CAS No. | 540737-29-9 |
| Ifarahan | Pa funfun si funfun lulú |
| Fọọmu Molecular | C16H20N6OC6H8O7 |
| Òṣuwọn Molikula | 504.50 |
| Ohun elo | Elegbogi ite tabi iwadi idi |
| Iṣakojọpọ | Gẹgẹbi ibeere rẹ |
| Ibi ipamọ | Fipamọ ni wiwọ, awọn apoti sooro ina ni aye tutu |
| Tofacitinib Citrate (CAS #540737-29-9) | ||
| NKANKAN | Awọn ajohunše | Esi |
| Ifarahan | Pa funfun si funfun lulú | Pa funfun lulú |
| Idanimọ | HPLC;IR;HNMR | Ibamu |
| Solubility | Soluble ni DMSO ni 100mg/milimita, tiotuka ti ko dara pupọ ninu ethanol, tiotuka ni omi diẹ ati bẹbẹ lọ. | Ibamu |
| Isonu lori Gbigbe | ≤0.5% | 0.12% |
| Aloku lori iginisonu | ≤0.1% | 0.05% |
| Awọn irin ti o wuwo | ≤10ppm | Ibamu |
| Awọn nkan ti o jọmọ | Diasteromer (RS+SR) ≤0.1% Aimọ Kankan ≤0.15% Lapapọ awọn idoti ≤1.0% | 0.05% 0.14% 0.18% |
| Enantiomorphism Isomers | ≤0.2% | Ibamu |
| Awọn ohun elo ti o ku | Ethanol ≤5000ppm Methanol ≤3000ppm Toluene ≤890ppm | Ibamu |
| Citrate akoonu | 36.2% ~ 40% | 37.8% |
| Mimo | ≥99.0% | 99.38% |
| Ayẹwo | 60.68% ~ 63.16% ti Tofacitinib INN 98% ~ 102% ti Tofacitinib Citrate INN | 62.04%
99.12% |
| Ipari: Ṣe ibamu | ||
Ile-iṣẹ Alaye
√ Iriri kikun ti Layer iṣakoso ni ile-iṣẹ ati awọn ọmọlẹyin awọn onimọ-ẹrọ oye; √ Didara nigbagbogbo jẹ akiyesi oke wa, Eto QC to muna; √ 11 ọdun ti o ni iriri ẹgbẹ tita ọja okeere; √ Lab R&D olominira; √ Awọn idanileko GMP igba pipẹ ti a fowo si; √ Awọn orisun ọlọrọ ti ọpọlọpọ awọn ile-iṣelọpọ laišišẹ fun iṣẹ akanṣe; √ Ẹgbẹ iṣẹ ṣiṣe ti o ga julọ pẹlu ọna deede.
Kọ ifiranṣẹ rẹ nibi ki o si fi si wa
